Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Aclara BioSciences and Tokyo Metropolitan Institute

June 17th, 2004

Aclara BioSciences and Tokyo Metropolitan Institute

Abstract:
Aclara BioSciences Inc. and the Tokyo Metropolitan Institute of Medical Science (Rinshoken) announced today that they have entered into an agreement to collaborate on a study to evaluate breast cancer patient samples to validate candidate biomarkers detected with ACLARA's proprietary eTag(TM) technology. This study follows previously completed feasibility experiments on a small set of tissue samples from patients treated with Genentech's drug Herceptin(R) and chemotherapy.

Source:
Aclara BioSciences

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Fine felted nanotubes : Research team of Kiel University develops new composite material made of carbon nanotubes November 22nd, 2017

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project